$1.8B Meningococcal Disease Market Analyzed in Epidemiological Forecast Report to 2025
PUNE, India, July 5, 2016 /PRNewswire/ --
RnRMarketResearch.com adds "EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2025" to its store providing an overview of the risk factors, comorbidities, and the global and historical trends for IMD in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). For the US, 5EU (France, Germany, Italy, Spain, and UK), and Brazil, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of all IMD (all serogroups combined), segmented by sex and age (in age groups of <1 year and 1-4 years, then in 10 year age groups to =65 years), and laboratory-confirmed incident cases of serogroup B, serogroup C, serogroup Y, and all other IMD combined. For Japan, it includes a 10-year epidemiological forecast for laboratory-confirmed incident cases of IMD segmented by sex and age (<1 year and =1 year); and a 10-year epidemiological forecast for laboratory-confirmed incident cases of specific serogroups. For the US, this report also provides a 10-year forecast of the number of first-year college students and the number of first-year college students living in campus accommodation.
Complete report on Meningococcal Disease Market Forecast to 2025 of 82 pages with 18 tables and 12 figures is now available at http://www.rnrmarketresearch.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2025-market-report.html .
Epidemiologists in this meningococcal disease market report forecast that the laboratory-confirmed incident cases of IMD will decrease from 4,153 cases in 2015 to 3,169 cases in 2025 at an Annual Growth Rate (AGR) of negative 2.37%. Brazil had the highest number of laboratory-confirmed incident cases of IMD among the individual markets of the 8MM throughout the forecast period. The 5EU combined will account for 45.32% of laboratory-confirmed incident cases in 2015, and by 2025 this is forecast to increase to 59.58%. In the 8MM in 2015, 43.37% of the laboratory-confirmed incident cases of IMD are serogroup C disease, 36.46% are serogroup B disease, 5.25% are serogroup Y disease, and 14.98% are disease caused by other serogroups combined. Epidemiologists of the 2016 meningococcal disease market research estimated that in the 8MM in 2015, 10.86% of laboratory-confirmed incident cases of IMD would occur in the population less than 1 year of age.
Order a copy of meningococcal disease market epidemiology forecast to 2025 research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=618641 .
Invasive meningococcal disease (IMD) is a life-threatening condition caused by the bacterium Neisseria meningitidis (N. meningitidis), an encapsulated gram-negative diplococcus that is a pathogen exclusive to humans. N. meningitidis is carried harmlessly in the nasopharynx of approximately 5?11% of adults and up to 25% of adolescents. Life-threatening disease occurs when the bacterium invades body tissue, which most commonly manifests as meningitis or septicemia. The disease is transmitted via respiratory droplets, through close or prolonged contact with an infected individual. N. meningitidis is classified into 13 distinct serogroups; however, almost all invasive disease in humans is a result of infection with one of 6 serogroups.
Another newly published market research titled MediPoint: Renal Denervation - Global Analysis and Market Forecasts to its database. Renal denervation catheters are categorized into the following: radiofrequency (RF) catheters, ultrasound catheters, and micro-injection catheters. Growth in the renal denervation market will be driven primarily by a need for a new intervention to treat resistant hypertension. This technology has the potential to revolutionize the cardiac field, providing a minimally invasive solution where none currently exist. The global market for renal denervation devices is dominated by Medtronic, St. Jude Medical, and Boston Scientific. Other key players include Cordis, ReCor Medical, and Terumo. Complete report on Renal Denervation market research report of 92 pages is available at http://www.rnrmarketresearch.com/medipoint-renal-denervation-global-analysis-and-market-forecasts-market-report.html .
Explore more reports on Infectious Diseases Therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/infectious-diseases-therapeutics .
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
Share this article